San Diego-based mostly Viking Therapeutics marked itself as a significant competitor during the weight loss drug current market in February just after revealing promising knowledge from the mid-stage trial of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when supplied for a weekly injection As well a